igf-1 lr3 pharmacokinetics half life Recombinant Human LR3-IGF-1(E51R) Protein Dietary or pharmacological inhibition of

doi: 10.1038/s41586-019-1705-2 46 ConradMPrattDA

Low vitamin C levels are commonly linked to fatigue and reduced focus

Reported side effects are rare and typically mild temporary redness or irritation at the application site, usually resolving quickly No documented systemic toxicity in research literature at typical therapeutic doses European Medicines Agency and independent research groups rate it as well-tolerated Compatible with most standard skincare routines when used with appropriate spacing from incompatible actives Contraindications and cautions Known sensitivity or allergy to copper compounds: avoid use Active skin infections or open wounds at the injection site: delay treatment Pregnancy and breastfeeding: insufficient safety data

Rojas-Morales P, Leon-Contreras JC, Aparicio-Trejo OE, Reyes-Ocampo JG, Medina-Campos ON, Jimenez-Osorio AS, et al

95100 30 820 1 27 /OPITAC 250mg C100mg C - 1CTOP1 2

Policy Note: This article is reprinted from the Cleveland Clinic Journal of Medicine (2023;90[7)]:439-447)